<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295776</url>
  </required_header>
  <id_info>
    <org_study_id>Lamictal PHN</org_study_id>
    <nct_id>NCT00295776</nct_id>
  </id_info>
  <brief_title>Lamictal in the Treatment of Post-Herpetic Neuralgia</brief_title>
  <official_title>Lamictal in the Treatment of Post-Herpetic Neuralgia-A Safety, Efficacy,Randomized, Double Blind, Placebo Controlled, Cross-Over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <brief_summary>
    <textblock>
      To assess the efficacy of Lamictal for the treatment of pain and reduction of allodynia in
      patients with post herpetic neuralgia.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    enrollment difficult due to inclusion/exclusion criteria/protocol requirements
  </why_stopped>
  <start_date>February 2005</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <condition>Neuralgia, Postherpetic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamictal in the treatment of Post-Herpetic Neuralgia</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients will be over the age of 18,

          -  Need to have a diagnosis of Post-Herpetic Neuralgia,

          -  Minimum of 4 on the Likert Pain Scale,

          -  If currently taking TCA and/or Gabapentin, need to have been on stable dose for
             minimum of 4 weeks

        Exclusion Criteria:

          -  Currently on any antiepileptic drugs (AED), except for Gabapentin.

          -  Currently taking opioid or unwilling to washout prior to the study,

          -  Pregnant and lactating,

          -  Have active severe systemic disease,

          -  History of Stevens-Johnson syndrome or TEN,

          -  Clinically significant abnormal lab values,

          -  Known drug allergy to Lamictal,

          -  Patients on Fibrates (Tricor and Lopid),

          -  History of major psychiatric disturbance and substance abuse.

          -  Valproate due to increase chances of severe rash,

          -  Lidocaine Patch,

          -  Use of hormonal contraceptives (birth control pills, patch, ring, injection)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Perry K. Richardson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Washington University Medical Faculty Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Faculty Associates</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2006</study_first_submitted>
  <study_first_submitted_qc>February 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>March 11, 2013</last_update_submitted>
  <last_update_submitted_qc>March 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inclusion Criteria:Minimum of 4 on the Likert Pain Scale.If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks.</keyword>
  <keyword>Exclusion Criteria:</keyword>
  <keyword>Currently on any antiepilepic drugs (AED), except for Gabapentin.</keyword>
  <keyword>Currently taking opioid or unwilling to washout prior to the study,</keyword>
  <keyword>Pregnant and lactating,</keyword>
  <keyword>Have active severe systemic disease,</keyword>
  <keyword>History of Stevens-Johnson syndrome or TEN,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

